Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Gene Regulation and Physiological Outcomes: Full Evidence Review

Previous related pageVitamin D, Gene Regulation and Physiological Outcomes: Study SummaryNext related pageVitamin D Receptor Activation and Co-Regulator Recruitment: Full Study
Study at a glance

What question did the studies ask?

Researchers asked how vitamin D-related changes in gene activity connect with tissue and whole-body outcomes. Gene activity produces RNA messages used by cells. A changed message does not automatically mean that a tissue works better. Most experiments used cells or animals; one included a year-long trial in older adults.

What did the researchers find?

Some mouse experiments linked receptor or gene-regulatory changes with calcium absorption, blood pressure, glucose handling or tissue scarring. An experiment using deliberately toxic injected vitamin D3 in mice found harmful mineral deposits. Another experiment found a large gene-response change without a clear resting mineral problem. Changes in nerve-insulating myelin structure or muscle fat did not establish better nerve performance or strength. In the human trial, vitamin D3 raised blood vitamin D but did not produce a clear gene response in the measured blood cells.

What does this mean?

The findings depended on the intervention, tissue and conditions. Removing a receptor, changing its partners, giving active hormone and taking vitamin D3 are different interventions. A measured outcome does not prove that one gene or protein contact caused it. Animal findings do not establish a general human treatment benefit or a personal dose.

Read the full article below ↓

Vitamin D-related gene regulation can accompany changes in calcium balance, metabolism, tissue structure and injury responses. Establishing that connection requires more than finding altered RNA: researchers must measure a physiological outcome and test which part of the regulatory pathway contributes to it. This review compares thirteen primary studies, including adverse and unclear findings, to examine that causal distance. For the shorter account, read Vitamin D, Gene Regulation and Physiological Outcomes: Study Summary.

What establishes a connection to physiology?

Transcription produces RNA messages from genes. Those messages can influence protein production, but RNA, protein and tissue performance are different measurements. Vitamin D and Gene Expression introduces this distinction. The vitamin D receptor, or VDR, can regulate transcription with other proteins; Vitamin D and Transcription Factors explains those partnerships. A receptor-dependent outcome is not automatically proof that one particular receptor: partner contact caused it.

The receptor belongs to the family described in Vitamin D and Nuclear Receptors. Removing it, altering one of its regulatory regions, restoring it to selected tissues and giving a ligand are different interventions. A ligand is a substance that binds a receptor. Calcitriol is the active vitamin D hormone; synthetic receptor activators and oral vitamin D3 are not interchangeable exposures. Vitamin D Receptors supplies the receptor background.

A convincing causal chain connects an intervention, a molecular change and a physiological measurement while testing competing explanations. Cell-specific perturbations can narrow the relevant tissue; restoring a missing component can test whether it is sufficient under the experimental conditions. Neither automatically identifies the sole mediator. Circulating minerals, hormones and developmental compensation can connect several organs. This focused comparison weighs those alternatives; it does not pool unlike experiments into an estimate of supplement benefit.

Intestinal rescue and whole-body calcium balance

Xue and Fleet restored human VDR mainly in the intestine of mice lacking their own receptor throughout the body. Two transgenic lines were studied. The principal comparison was with mice carrying one functional Vdr copy, rather than a generic wild-type group. In the tested conditions, rescue recovered measured intestinal calcium absorption, growth and serum calcium and parathyroid hormone contrasts. Parathyroid hormone helps regulate calcium balance. These are linked tissue and whole-animal observations, beyond a list of responsive genes. [1]

Selected intestinal calcium-transport transcripts also responded, but the responses were not identical to those in receptor-positive comparators. Restored absorption therefore cannot simply be assigned to one measured transcript. The rescue did not correct every phenotype: hair loss remained. Detectable kidney transgene signal also prevents describing the manipulation as perfectly intestine-exclusive. [1]

This is a sufficiency experiment on a global-null background, not an intestine-specific deletion establishing necessity. Restoring a receptor restores several possible functions together; the experiment does not isolate nuclear transcription as the only route to absorption. Basal measurements in twelve-week male mice and acute absorption experiments in eight-week females also represent different conditions. Engineered expression, development and endocrine feedback constrain transfer to ordinary human vitamin D intake. [1]

Changed transcription without a major basal mineral phenotype

Meyer and colleagues mutated regulatory DNA near the mouse Cyp24a1 gene, which contributes to vitamin D metabolite breakdown. One line altered two proximal vitamin D response elements and an adjacent AP1 site; another altered the second response element alone. The double-region mutation markedly reduced induced Cyp24a1 expression and receptor occupancy in kidney and intestine. It did not delete the receptor throughout the animal. [2]

Despite that molecular impairment, the investigators detected no statistically significant basal difference in serum calcium, phosphate, parathyroid hormone, intact FGF23 or body weight in the tested young mice. FGF23 is a hormone involved in phosphate regulation. Some vitamin D metabolites did change, so this was not an absence of every biochemical consequence. [2]

This contrast challenges a simple assumption that a large induced transcriptional change must produce a large resting mineral phenotype. It does not prove physiological equivalence. Other regulatory regions and compensatory responses may help preserve the measured endpoints; young animals on a standard diet do not test all ages, stresses or disease states. The adjacent AP1 mutation also prevents attributing every result solely to two vitamin D response elements. [2]

An altered receptor can differ from an absent receptor

Doms and colleagues compared mice lacking VDR with mice carrying a receptor missing its final activation region, called AF2. The altered receptor failed to recruit the tested coactivator proteins normally after ligand exposure and lacked classical reporter activation, while retaining interactions with corepressors. Coactivators and corepressors are proteins that can help increase or restrain gene activity. The receptor was therefore altered, rather than simply absent. [3]

The AF2-mutant mice developed more severe mineral and bone abnormalities than receptor-null mice. A diet rich in calcium, phosphate and lactose largely corrected the null animals’ mineral phenotype but did not similarly correct the mutant phenotype. The comparison shows why two interventions loosely described as loss of receptor function can have different whole-animal consequences. The broader mineral context is explained in Vitamin D and Bone. [3]

Changes restricted to osteochondrogenic or myeloid lineages did not reproduce the profound systemic phenotype. This supports a substantial contribution from outside those skeletal lineages and from mineral supply. These genetic labels do not identify perfectly pure cell populations, however, and incomplete deletion limits the negative myeloid result. The main systemic comparisons used eight-week females. [3]

Reduced intestinal transport-gene expression was consistent with the physiological findings but did not identify a specific direct repression event as their cause. Exploratory RNA comparisons used nominal significance criteria, with inconsistent reported fold-change thresholds; an exact validated target count is not warranted. Endocrine state and tissue composition can also alter RNA. Coactivator-independent activity is not the same claim as universal ligand independence. [3]

Renin regulation and blood pressure

Li and colleagues studied renin, a component of the hormone system controlling blood pressure and fluid balance. Global Vdr-null mice had higher renal renin and circulating angiotensin II, alongside raised arterial pressure measured under anaesthesia. Captopril reduced the pressure difference between genotypes. Salt and dehydration responses remained, suggesting a changed baseline rather than abolition of physiological regulation. [4]

In engineered mouse kidney-derived cells expressing human VDR, calcitriol suppressed renin RNA and a renin-promoter reporter. Vector-only cells did not show the same response. This supports receptor-dependent transcriptional regulation in that cell model. The paper did not map a negative vitamin D response element or establish the complete molecular route from promoter regulation to the animal’s blood pressure. [4]

Calcium-normalizing diets and young normocalcemic animals argued against low calcium as the sole explanation. Raised parathyroid hormone and other consequences of congenital whole-body receptor loss remained possible contributors. Several intervention groups were small, and the engineered cell line was not normal human kidney tissue. The linked cell and animal findings do not establish that vitamin D3 supplements treat hypertension. [4]

Developmental programming and metabolic responses

Oh and colleagues transferred mixed fetal-liver cells from developing mouse offspring of vitamin D-deficient or sufficient mothers into irradiated recipients maintained with sufficient vitamin D. The transferred mixture included blood-forming stem cells; it was not a purified stem-cell preparation. Altered insulin responses persisted after primary and secondary transfers, connecting developmental conditions with a transferable metabolic phenotype. Insulin helps regulate glucose use, as explained in Vitamin D and Insulin Signalling. [5]

The investigators linked the response to a programme involving JARID2, PGC-1alpha and a small regulatory RNA, miR-106b-5p. JARID2 is a regulator associated with a chromatin-modifying complex, not that complex’s catalytic enzyme. Genetic and regulatory-RNA perturbations added causal evidence: inhibiting the selected small RNA improved the tested adipocyte response, whereas neutralizing several elevated inflammatory cytokines did not restore glucose uptake in that experiment. Raised inflammatory signals alone therefore did not establish mediation. [5]

The work does not demonstrate a physical VDR: JARID2 complex or show that a particular DNA methylation site caused persistence. Developmental deficiency, irradiation and cell transplantation are strong interventions. The human branch used observational maternal/cord samples and tested conditioned media on mouse adipocytes; it did not follow supplemented mothers’ children to establish diabetes prevention. Persistent regulatory change and human treatment efficacy remain separate questions. Vitamin D and Epigenetic Regulation explains the wider regulatory context. [5]

Cofactor switching and mouse glucose control

Wei and colleagues investigated VDR-associated complexes that change how DNA is packaged. Protein-binding and perturbation experiments supported a switch involving BRD9: and BRD7-associated complexes. The physiological experiments combined calcipotriol, a synthetic receptor activator, with an inhibitor of BRD9. Mouse glucose tolerance, fasting glucose, insulin and pancreatic-islet measurements provided outcomes beyond gene activity alone. [6]

The combination mattered: single agents had limited or absent benefit in some severe models, and results differed by model. These were partial experimental improvements, not a demonstration that ordinary vitamin D3 normalized diabetes. The human-islet experiments were performed outside the body; they were not a clinical treatment trial. [6]

The animal experiments did not selectively restore one receptor: cofactor interface only in beta cells, the pancreatic cells that produce insulin. Other tissues and drug effects therefore remain possible contributors. Male-only models, small groups and limited biological RNA replicates constrain certainty. Changes maintained during ongoing exposure also do not demonstrate lasting effects after treatment stops. This programme overlaps in investigators with the liver study below; the two papers test distinct mechanisms and are not independent-laboratory replications of one treatment effect. [6] [8]

Transcriptional repression and kidney injury

Ito and colleagues connected molecular repression with outcomes in mouse kidney-injury models. Purified VDR and SMAD3 domains interacted, and experiments supported interference with SMAD3 binding to DNA. Receptor variants unable to perform ordinary vitamin D response-element activation still repressed a SMAD-dependent reporter. This distinguishes one form of transcriptional repression from classical receptor-mediated activation; it does not make the mechanism nontranscriptional. [7]

Calcitriol reduced selected fibrosis-related transcripts and tissue scarring in an obstruction model. Experimental ligands designed to separate repression from strong classical activation also reduced fibrosis. A longer folic-acid injury model included improved creatinine, a kidney-function marker, as well as tissue findings. The molecular and physiological experiments thus provide a more developed chain than marker expression alone. [7]

The chain is still bounded by model and exposure. Small mouse groups and multiple statistical comparisons limit precision. Calcitriol raised calcium, and a slight longer-term calcium increase with an experimental ligand prevents a claim of completely noncalcemic safety. These agents are not ordinary vitamin D3 or established human kidney treatments. Repression in a reporter does not prove that the same mechanism is sufficient in every renal disease. [7]

A different regulatory route to less liver scarring

Ding and colleagues examined hepatic stellate cells, which contribute to liver scarring. These liver cells are different from the blood-forming stem cells discussed above. Regulatory-region occupancy and protein-depletion experiments supported context-dependent cooperation and opposition between VDR and SMAD3. The evidence concerns their genomic behaviour; it does not supply the purified direct-binding result demonstrated separately in the kidney study. [8] [7]

In a carbon-tetrachloride mouse injury model, calcipotriol reduced fibrosis assessed through pathology, collagen-related measurements and gene expression. Histological assessment was blinded. These are tissue-structural consequences, not proof of improved human liver failure or a clinical treatment effect. Global receptor-loss comparisons likewise do not isolate a stellate-cell-specific causal route. [8]

Not every genomic site or nearby assigned gene was individually tested for necessity. A quantitative analysis of two selected, less-fibrotic null livers also cannot be treated as an unbiased estimate from all null animals. The work supports a distinct regulatory avenue linked with tissue architecture while leaving the complete pathway to organ function unresolved. [8]

A harmful physiological outcome

Han and colleagues connected receptor/RUNX2 cooperation with vascular mineral deposition. Cultured vascular cells showed regulatory and mineralization responses, while global Vdr-null and RUNX2-mutant mice were tested under deliberately toxic injected vitamin D3 exposure. RUNX2 is a gene-regulating protein involved in bone-related programmes. This is pathological mineral deposition in vessels, not a demonstration of desirable tissue repair. [9]

RUNX2-mutant animals were protected despite raised calcium, an informative contrast. Vdr-null animals also lacked the usual calcium rise, making their protection harder to separate from systemic mineral effects. Protein association measured in transfected cells did not prove a selective native vascular binding interface caused the whole-animal result. No cardiac performance, cardiovascular-event or survival benefit was established. The exposure cannot be used to infer harm from ordinary oral intake. [9]

Myelin-associated structure is not nerve performance

De la Fuente and colleagues studied rat cells already capable of becoming myelin-producing cells. Myelin insulates nerve fibres. VDR perturbation changed maturation, and antagonism reduced myelin-associated structure and repair in cerebellar slices. The study provides a local tissue consequence, not a measured whole-animal neurological benefit. Vitamin D and Cell Differentiation explains the distinction between cellular maturation and broader tissue function. [10]

Added calcitriol initially gave no extra differentiation response in cells derived using normal serum. A response appeared with prior charcoal-treated serum, which also alters other steroid exposures. Receptor-partner association and receptor inhibition did not selectively isolate the physical partner interface. Slice measurements did not establish improved electrical conduction, behaviour or human repair. Those are further outcomes, not interchangeable labels for more myelin staining. [10]

Muscle composition is not muscle strength

Hosoyama and colleagues found that calcitriol inhibited fat-cell development from mouse muscle mesenchymal progenitors, and receptor deletion removed that inhibition. Cell-specific receptor loss worsened fatty infiltration under selected injury or atrophy conditions. Dietary deficiency produced the fat phenotype in old but not young mice. These distinctions make the biological setting part of the result. [11]

RUNX1 protein decreased while its RNA did not. That discordance prevents describing the finding as demonstrated transcriptional repression of RUNX1. No RUNX1 rescue or physical VDR: RUNX1 complex test established the proposed pathway. Muscle-fibre area did not change, and force was not measured. The accompanying human muscle study did not measure blood vitamin D. Neither reduced tissue fat nor the human age association establishes improved strength from supplementation. [11]

Selected hair-cycle rescue without conventional ligand binding

Skorija and colleagues expressed human receptor variants in the skin of global Vdr-null mice. A receptor unable to bind hormone normally nevertheless restored selected early hair-regrowth and longer-term coat outcomes. Another activation-region mutant had a different longer-term rescue pattern. These results separate receptor presence from conventional ligand action. [12]

They do not show that every skin or receptor function is ligand-independent. Transgenic expression differs from the native setting, and retained association with the Hairless regulator did not establish that one specific interface alone caused rescue. Extra vitamin D cannot be assumed to substitute for a missing receptor. The broader regeneration question requires the same separation of molecular mechanism and recovered tissue performance, discussed in Vitamin D and Regeneration. [12]

The human translation boundary

The BEST-D trial assigned 305 adults aged at least 65 years to oral vitamin D3 or placebo for twelve months. The active regimens were 2,000 or 4,000 international units daily; these are research exposures, not personal treatment instructions. Gene-expression data were available for 298 participants, with 262 paired baseline/end measurements. Random assignment and placebo comparison distinguish this trial from uncontrolled before-and-after studies. [13]

Vitamin D status rose in the active groups, but the primary placebo-controlled analysis found no gene significant at the stated 5% false-discovery threshold. Selected circulating cytokines also showed no convincing change. Nominal or within-treatment comparisons did not overturn that controlled result. A higher blood vitamin D concentration is therefore not itself evidence of the claimed downstream response; Vitamin D Status vs Vitamin D Effect explains that distinction. [13]

The trial sampled mixed whole blood at a late time point in a particular older population, rather than specifically recruiting for severe deficiency. It cannot rule out earlier effects, particular cell subsets, other tissues or smaller responses. Nor did this genomic analysis test every physiological outcome in the animal studies. Its proper contribution is a human translation boundary, not proof that vitamin D has no biological effects. [13]

Comparing the experimental links

InterventionMeasured consequenceRemaining causal limit
Mainly intestinal receptor rescueCalcium absorption, growth and blood calcium/PTHRestoration does not isolate transcription as the sole mediator. [1]
Promoter-region mutationImpaired induced RNA response without detected major basal mineral changeCompensation and adjacent AP1 mutation limit attribution. [2]
Activation-region deletionSevere mineral/bone phenotype despite dietary rescueAn altered receptor is not equivalent to no receptor. [3]
Experimental pathway or drug interventionsSelected glucose, kidney-injury and liver-structure outcomesCombination, tissue and mechanism specificity remain incomplete. [5 to 8]
Toxic injected vitamin D3Pathological vascular mineral depositionNot evidence about ordinary oral intake. [9]
Local cell/tissue interventionsMyelin-associated structure, muscle fat or hair-cycle outcomesThese do not establish general nerve, muscle or systemic performance. [10 to 12]
Randomized oral vitamin D3No clear late whole-blood gene/cytokine responseDoes not exclude other times, tissues or smaller effects. [13]

What these studies establish together

The strongest comparisons intervene at different points: restoring a receptor, altering a regulatory DNA region, removing an activation surface, changing a downstream regulator or combining experimental drugs. Their outcomes also differ: absorption, pressure, glucose handling, tissue scarring, mineral deposition and local structure. A finding can support one link in a causal chain while leaving the next link uncertain. Several assays within one paper do not become independent studies, and repeated use of a paper across questions does not multiply the evidence.

The findings include recovery, harmful change and no detected difference. They show why neither receptor presence nor more transcription predicts one universally beneficial physiological direction. They also show why local structure should not be promoted to whole-organ performance, or an animal mechanism to a human treatment effect. The selected evidence supports specific connections between vitamin D-related regulation and physiology, with substantial remaining mediation and translation limits. It does not establish a personal dose or a general supplement strategy for improving all these outcomes.

Scientific sources

[1] Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Xue Y, Fleet JC. Gastroenterology. 2009;136(4):1317-27, e1-2. DOI 10.1053/j.gastro.2008.12.051; PMID 19254681; PMCID PMC2695717.

[2] In Vivo Contribution of Cyp24a1 Promoter Vitamin D Response Elements. Meyer MB, Lee SM, Towne JM, Cichanski SR, Kaufmann M, Jones G, Pike JW. Endocrinology. 2024;165(11):bqae134. DOI 10.1210/endocr/bqae134; PMID 39363152; PMCID PMC11487884.

[3] Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose. Doms S, Verlinden L, Janssens I, Vanhevel J, Eerlings R, Houtman R, Kato S, Mathieu C, Decallonne B, Carmeliet G, Verstuyf A. Bone research. 2024;12(1):44. DOI 10.1038/s41413-024-00343-7; PMID 39164247; PMCID PMC11335873.

[4] 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. The Journal of clinical investigation. 2002;110(2):229-38. DOI 10.1172/JCI15219; PMID 12122115; PMCID PMC151055.

[5] Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. Oh J, Riek AE, Bauerle KT, Dusso A, McNerney KP, Barve RA, Darwech I, Sprague JE, Moynihan C, Zhang RM, Kutz G, Wang T, Xing X, Li D, Mrad M, Wigge NM, Castelblanco E, Collin A, Bambouskova M, Head RD, Sands MS, Bernal-Mizrachi C. Nature communications. 2023;14(1):3278. DOI 10.1038/s41467-023-38849-z; PMID 37311757; PMCID PMC10264405.

[6] Vitamin D Switches BAF Complexes to Protect β Cells. Wei Z, Yoshihara E, He N, Hah N, Fan W, Pinto AFM, Huddy T, Wang Y, Ross B, Estepa G, Dai Y, Ding N, Sherman MH, Fang S, Zhao X, Liddle C, Atkins AR, Yu RT, Downes M, Evans RM. Cell. 2018;173(5):1135-1149.e15. DOI 10.1016/j.cell.2018.04.013; PMID 29754817; PMCID PMC5987229.

[7] A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. The Journal of clinical investigation. 2013;123(11):4579-4594. DOI 10.1172/jci67804; PMID 24135137; PMCID PMC3809783.

[8] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. Cell. 2013;153(3):601-613. DOI 10.1016/j.cell.2013.03.028; PMID 23622244; PMCID PMC3673534.

[9] Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification. Han MS, Che X, Cho GH, Park HR, Lim KE, Park NR, Jin JS, Jung YK, Jeong JH, Lee IK, Kato S, Choi JY. PloS one. 2013;8(12):e83584. DOI 10.1371/journal.pone.0083584; PMID 24349534; PMCID PMC3861528.

[10] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. de la Fuente AG, Errea O, van Wijngaarden P, Gonzalez GA, Kerninon C, Jarjour AA, Lewis HJ, Jones CA, Nait-Oumesmar B, Zhao C, Huang JK, ffrench-Constant C, Franklin RJ. The Journal of cell biology. 2015;211(5):975-985. DOI 10.1083/jcb.201505119; PMID 26644513; PMCID PMC4674280.

[11] Lack of vitamin D signalling in mesenchymal progenitors causes fatty infiltration in muscle. Hosoyama T, Kawai-Takaishi M, Iida H, Yamamoto Y, Nakamichi Y, Watanabe T, Takemura M, Kato S, Uezumi A, Matsui Y. Journal of cachexia, sarcopenia and muscle. 2024;15(3):907-918. DOI 10.1002/jcsm.13448; PMID 38533539; PMCID PMC11154772.

[12] Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.). 2005;19(4):855-862. DOI 10.1210/me.2004-0415; PMID 15591533.

[13] Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial. Berlanga-Taylor AJ, Plant K, Dahl A, Lau E, Hill M, Sims D, Heger A, Emberson J, Armitage J, Clarke R, Knight JC. EBioMedicine. 2018;31:133-142. DOI 10.1016/j.ebiom.2018.04.010; PMID 29685792; PMCID PMC6013786.

Related reading

Original sources

Source

In Vivo Contribution of Cyp24a1 Promoter Vitamin D Response Elements.

Published in Meyer MB, Lee SM, Towne JM, Cichanski SR, Kaufmann M, Jones G, Pike JW. Endocrinology (2024).

Publication details

[2] In Vivo Contribution of Cyp24a1 Promoter Vitamin D Response Elements. Meyer MB, Lee SM, Towne JM, Cichanski SR, Kaufmann M, Jones G, Pike JW. Endocrinology. 2024;165(11):bqae134. DOI 10.1210/endocr/bqae134; PMID 39363152; PMCID PMC11487884.

Read more →
Source

Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose.

[3] Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose.

Publication details

[3] Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose. Doms S, Verlinden L, Janssens I, Vanhevel J, Eerlings R, Houtman R, Kato S, Mathieu C, Decallonne B, Carmeliet G, Verstuyf A. Bone research. 2024;12(1):44. DOI 10.1038/s41413-024-00343-7; PMID 39164247; PMCID PMC11335873.

Read more →
Source

Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes

Environmental factors may alter the fetal genome to cause metabolic diseases.

Publication details

[5] Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. Oh J, Riek AE, Bauerle KT, Dusso A, McNerney KP, Barve RA, Darwech I, Sprague JE, Moynihan C, Zhang RM, Kutz G, Wang T, Xing X, Li D, Mrad M, Wigge NM, Castelblanco E, Collin A, Bambouskova M, Head RD, Sands MS, Bernal-Mizrachi C. Nature communications. 2023;14(1):3278. DOI 10.1038/s41467-023-38849-z; PMID 37311757; PMCID PMC10264405.

Read more →
Source

Vitamin D Switches BAF Complexes to Protect β Cells.

[6] Vitamin D Switches BAF Complexes to Protect β Cells.

Publication details

[6] Vitamin D Switches BAF Complexes to Protect β Cells. Wei Z, Yoshihara E, He N, Hah N, Fan W, Pinto AFM, Huddy T, Wang Y, Ross B, Estepa G, Dai Y, Ding N, Sherman MH, Fang S, Zhao X, Liddle C, Atkins AR, Yu RT, Downes M, Evans RM. Cell. 2018;173(5):1135-1149.e15. DOI 10.1016/j.cell.2018.04.013; PMID 29754817; PMCID PMC5987229.

Read more →
Source

A nonclassical vitamin D receptor pathway suppresses renal fibrosis.

[7] A nonclassical vitamin D receptor pathway suppresses renal fibrosis.

Publication details

[7] A nonclassical vitamin D receptor pathway suppresses renal fibrosis. Ito I, Waku T, Aoki M, Abe R, Nagai Y, Watanabe T, Nakajima Y, Ohkido I, Yokoyama K, Miyachi H, Shimizu T, Murayama A, Kishimoto H, Nagasawa K, Yanagisawa J. The Journal of clinical investigation. 2013;123(11):4579-4594. DOI 10.1172/jci67804; PMID 24135137; PMCID PMC3809783.

Read more →
Source

A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.

[8] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response.

Publication details

[8] A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. Cell. 2013;153(3):601-613. DOI 10.1016/j.cell.2013.03.028; PMID 23622244; PMCID PMC3673534.

Read more →
Source

Functional Cooperation between Vitamin D Receptor and Runx2 in Vitamin D-Induced Vascular Calcification

The transdifferentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells has been implicated in the context of vascular calcification.

Publication details

[9] Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification. Han MS, Che X, Cho GH, Park HR, Lim KE, Park NR, Jin JS, Jung YK, Jeong JH, Lee IK, Kato S, Choi JY. PloS one. 2013;8(12):e83584. DOI 10.1371/journal.pone.0083584; PMID 24349534; PMCID PMC3861528.

Read more →
Source

Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.

[10] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.

Publication details

[10] Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation. de la Fuente AG, Errea O, van Wijngaarden P, Gonzalez GA, Kerninon C, Jarjour AA, Lewis HJ, Jones CA, Nait-Oumesmar B, Zhao C, Huang JK, ffrench-Constant C, Franklin RJ. The Journal of cell biology. 2015;211(5):975-985. DOI 10.1083/jcb.201505119; PMID 26644513; PMCID PMC4674280.

Read more →
Source

Lack of vitamin D signalling in mesenchymal progenitors causes fatty infiltration in muscle.

[11] Lack of vitamin D signalling in mesenchymal progenitors causes fatty infiltration in muscle.

Publication details

[11] Lack of vitamin D signalling in mesenchymal progenitors causes fatty infiltration in muscle. Hosoyama T, Kawai-Takaishi M, Iida H, Yamamoto Y, Nakamichi Y, Watanabe T, Takemura M, Kato S, Uezumi A, Matsui Y. Journal of cachexia, sarcopenia and muscle. 2024;15(3):907-918. DOI 10.1002/jcsm.13448; PMID 38533539; PMCID PMC11154772.

Read more →
Source

Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis.

Published in Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.) (2005).

Publication details

[12] Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Skorija K, Cox M, Sisk JM, Dowd DR, MacDonald PN, Thompson CC, Demay MB. Molecular endocrinology (Baltimore, Md.). 2005;19(4):855-862. DOI 10.1210/me.2004-0415; PMID 15591533.

Read more →
Source

Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial.

[13] Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial.

Publication details

[13] Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial. Berlanga-Taylor AJ, Plant K, Dahl A, Lau E, Hill M, Sims D, Heger A, Emberson J, Armitage J, Clarke R, Knight JC. EBioMedicine. 2018;31:133-142. DOI 10.1016/j.ebiom.2018.04.010; PMID 29685792; PMCID PMC6013786.

Read more →